等待開盤 06-25 09:30:00 美东时间
-7.260
-8.72%
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Mizuho analyst Joseph Catanzaro downgraded Apogee Therapeutics Inc (NASDAQ:APGE) from Outperform ...
06-24 20:17
Raymond James analyst Brian Gesuale downgrades V2X (NYSE:VVX) from Outperform to Market Perform.
06-24 18:13
V2X, Inc. (NYSE:VVX), today announced the successful repricing of its approximately $869 million First Lien Term Loan. The repricing improves the applicable interest rate to SOFR plus an applicable margin of 2.0%, with
06-03 19:35
V2X reprices $869 million first-lien term loan to SOFR+2% margin V2X repriced about $869 million of its First Lien Term Loan, cutting the rate to SOFR plus 2%. Terms include a further 25-basis-point margin reduction if it secures Ba3 from Moody’s and BB from S&P, both stable. The SOFR floor dropped
06-03 19:31
今日重点评级关注:Ascendiant Capital:维持Aclarion"买入"评级,目标价从7美元升至7.5美元;Susquehanna:维持美光科技"积极"评级,目标价从600美元升至1750美元
06-01 14:11
Shares of aerospace and defense companies are trading higher on reports the Tru...
05-29 03:52
V2X Inc. (VVX) on Monday said it won a contract from the U.S. Navy’s Naval Air Systems Command to support the Large Aircraft Infrared Countermeasures program, which protects military aircraft from inf...
05-18 20:07
RESTON, Va., May 18, 2026 /PRNewswire/ -- V2X, Inc. (NYSE: VVX) has been awarded a contract by the U.S. Navy's Naval Air Systems Command to support the Large Aircraft Infrared Countermeasure...
05-18 19:30
V2X prices 2 million-share secondary offering at $74.35 per share V2X priced a secondary offering of 2 million shares sold by Vertex Aerospace at USD 74.35 per share. V2X is not selling any shares in the deal, so it will not receive proceeds. Closing expected on or about May 11, 2026, subject to cus
05-08 08:27
今日重点评级关注:Piper Sandler:维持Aclaris Therapeutics"超配"评级,目标价从7美元升至11美元;Evercore ISI集团:维持BioMarin Pharmaceutical"跑赢大市"评级,目标价从110美元升至120美元
05-06 11:29